AI assistant
ASPEN INSURANCE HOLDINGS LTD — Proxy Solicitation & Information Statement 2014
Jul 1, 2014
31292_psi_2014-07-01_bf65d2b9-c35f-47a0-b7fb-ac04e83aec30.zip
Proxy Solicitation & Information Statement
Open in viewerOpens in your device viewer
DFAN14A 1 d752942ddfan14a.htm DEFINITIVE ADDITIONAL MATERIALS DEFINITIVE ADDITIONAL MATERIALS
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ¨ Filed by a Party other than the Registrant x
Check the appropriate box:
¨ Preliminary Proxy Statement
¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨ Definitive Proxy Statement
x Definitive Additional Materials
¨ Soliciting Material under §240.14a12
ASPEN INSURANCE HOLDINGS LIMITED
(Name of Registrant as Specified In Its Charter)
ENDURANCE SPECIALTY HOLDINGS LTD.
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
x No fee required.
¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
-
Title of each class of securities to which transaction applies:
-
Aggregate number of securities to which transaction applies:
-
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
-
Proposed maximum aggregate value of transaction:
-
Total fee paid:
¨ Fee paid previously with preliminary materials:
¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
-
Amount Previously Paid:
-
Form, Schedule or Registration Statement No.:
-
Filing Party:
-
Date Filed:
Endurance Endurance and Aspen: Creating a Global Leader in Specialty Insurance and Reinsurance July 2014
Forward looking statements & other information Cautionary Note Regarding Forward Looking Statements Some of the statements in this presentation may include, and Endurance may make related oral, forward-looking statements which reflect our current views with respect to future events and financial performance. Such statements may include forward-looking statements both with respect to us in general and the insurance and reinsurance sectors specifically, both as to underwriting and investment matters. These statements may also include assumptions about our proposed acquisition of Aspen (including its benefits, results, effects and timing). Statements which include the words should, would, expect, intend, plan, believe, project, target, anticipate, seek, will, deliver, and similar statements of a future or forward-looking nature identify forward-looking statements in this presentation for purposes of the U.S. federal securities laws or otherwise. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the Private Securities Litigation Reform Act of 1995, except to the extent made in connection with Endurances exchange offer. All forward-looking statements address matters that involve risks and uncertainties. Accordingly, there are or may be important factors that could cause actual results to differ materially from those indicated in the forward-looking statements. These factors include, but are not limited to, the effects of competitors pricing policies, greater frequency or severity of claims and loss activity, changes in market conditions in the agriculture insurance industry, termination of or changes in the terms of the U.S. multiple peril crop insurance program, a decreased demand for property and casualty insurance or reinsurance, changes in the availability, cost or quality of reinsurance or retrocessional coverage, our inability to renew business previously underwritten or acquired, our inability to maintain our applicable financial strength ratings, our inability to effectively integrate acquired operations, uncertainties in our reserving process, changes to our tax status, changes in insurance regulations, reduced acceptance of our existing or new products and services, a loss of business from and credit risk related to our broker counterparties, assessments for high risk or otherwise uninsured individuals, possible terrorism or the outbreak of war, a loss of key personnel, political conditions, changes in accounting policies, our investment performance, the valuation of our invested assets, a breach of our investment guidelines, the unavailability of capital in the future, developments in the worlds financial and capital markets and our access to such markets, government intervention in the insurance and reinsurance industry, illiquidity in the credit markets, changes in general economic conditions and other factors described in our Annual Report on Form 10-K for the year ended December 31, 2013 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014. Additional risks and uncertainties related to the proposed transaction include, among others, uncertainty as to whether Endurance will be able to enter into or consummate the transaction on the terms set forth in the proposal, the risk that our or Aspens shareholders do not approve the transaction, potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, uncertainties as to the timing of the transaction, uncertainty as to whether Aspen shareholders tender into the exchange offer, uncertainty as to the actual premium of the Endurance share component of the proposal that will be realized by Aspen shareholders in connection with the transaction, competitive responses to the transaction, the risk that regulatory or other approvals required for the transaction are not obtained or are obtained subject to conditions that are not anticipated, the risk that the conditions to the closing of the transaction are not satisfied, costs and difficulties related to the integration of Aspens businesses and operations with Endurances businesses and operations, the inability to obtain, or delays in obtaining, cost savings and synergies from the transaction, unexpected costs, charges or expenses resulting from the transaction, litigation relating to the transaction, the inability to retain key personnel, and any changes in general economic and/or industry specific conditions. Forward-looking statements speak only as of the date on which they are made, and we undertake no obligation publicly to update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and elsewhere, including the risk factors included in our most recent reports on Form 10-K and Form 10-Q and the risk factors included in Aspens most recent reports on Form 10-K and Form 10-Q and other documents of Endurance and Aspen on file with the U.S. Securities and Exchange Commission (the SEC). Any forward-looking statements made in this presentation are qualified by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by Endurance will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us or our business or operations. Additional Information and Where to Find It This presentation relates to the offer commenced by Endurance to exchange each issued and outstanding common share of Aspen (together with associated preferred share purchase rights) for $49.50 in cash, 0.9197 Endurance common shares, or a combination of cash and Endurance common shares, subject to a customary proration mechanism. This presentation is for informational purposes only and does not constitute an offer to exchange, or a solicitation of an offer to exchange, Aspen common shares, nor is it a substitute for the Tender Offer Statement on Schedule TO or the preliminary Prospectus/Offer to Exchange included in the Registration Statement on Form S-4 (including the Letter of Transmittal and Election and related documents and as amended from time to time, the Exchange Offer Documents) that Endurance has filed with the SEC. The Endurance exchange offer will be made only through the Exchange Offer Documents. This presentation is not a substitute for any other relevant documents that Endurance may file with the SEC or any other documents that Endurance may send to its or Aspens shareholders in connection with the proposed transaction. Endurance has sent to Aspen shareholders a solicitation statement with respect to the solicitation of (i) written requisitions that the board of directors of Aspen convene a special general meeting of Aspens shareholders to vote on an increase in the size of Aspens board of directors from 12 to 19 directors and (ii) Aspen shareholder support for the proposal of a scheme of arrangement by Endurance which will entail the holding of a court-ordered meeting of Aspen shareholders at which Aspens shareholders would vote to approve a scheme of arrangement under Bermuda law pursuant to which Endurance would acquire all of Aspens outstanding common shares on financial terms no less favorable than those contained in its acquisition proposal announced on June 2, 2014 (the Solicitation Statement). INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE EXCHANGE OFFER DOCUMENTS AND THE SOLICITATION STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ENDURANCE HAS FILED OR MAY FILE WITH THE SEC IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. All such documents, when filed, are available free of charge at the SECs website (www.sec.gov) or by directing a request to Endurance, +1 441 278 0988 (phone), [email protected] (email). Participants in the Solicitation Endurance and its directors and certain of its executive officers and employees may be deemed to be participants in any solicitation of shareholders in connection with the proposed transaction. Information about Endurances directors, executive officers and employees who may be deemed to be participants in the solicitation, including a description of their direct and indirect interests, by security holdings or otherwise, is set forth in the Solicitation Statement and Endurances proxy statement, dated April 9, 2014, for its 2014 annual general meeting of shareholders. 2 Endurance
Forward looking statements & other information (continued) Regulation G Disclaimer In this presentation, management has included and discussed certain non-GAAP measures, including return on equity, combined ratio, net premiums written and diluted book value per share. Management believes that these non-GAAP measures, which may be defined differently by other companies, better explain the proposed transaction in a manner that allows for a more complete understanding. However, these measures should not be viewed as a substitute for those determined in accordance with GAAP. For a complete description of non-GAAP measures and reconciliations, please review the Investor Financial Supplement on our web site at www.endurance.bm. Third Party-Sourced Information Certain information included in this presentation has been sourced from third parties. Endurance does not make any representations regarding the accuracy, completeness or timeliness of such third party information. Permission to cite such information has neither been sought nor obtained. All information in this presentation regarding Aspen, including its businesses, operations and financial results, was obtained from public sources. While Endurance has no knowledge that any such information is inaccurate or incomplete, Endurance has not had the opportunity to verify any of that information. Additional Information All references in this presentation to $ refer to United States dollars. The contents of any website referenced in this presentation are not incorporated by reference herein. 3 Endurance
Table of Contents Executive Summary Strategic Rationale and Compelling Value of Endurances Proposal Endurances Actions to Expedite the Transaction Appendix 4 Endurance
Endurance Executive Summary
Industry Overview Primary insurers provide insurance coverage (a promise to pay) in return for premiums Investment income is earned on the premiums, which are invested before claims are paid out Reinsurers provide insurance for insurance companies looking to lay-off (cede) a portion of their assumed risk Bermuda is a leading global insurance and reinsurance market, particularly for specialty risks Endurance Specialty Holdings Ltd., based in Bermuda, is a provider of specialty lines of property and casualty insurance and reinsurance worldwide Endurances common shares are listed on the NYSE under the symbol ENH Aspen Insurance Holdings Limited provides insurance and reinsurance coverage to clients in various domestic and international markets and is based in Bermuda Aspens common shares are listed on the NYSE under the symbol AHL Shareholders Equity of Peer Companies (1) $Bn, as of 3/31/2014 12.0 10.2 10.0 8.0 6.0 4.0 2.0 0.0 XL 7.0 RE 6.8 PRE 5.9 ACGL 5.8 AXS 3.8 RNR 3.6 VR 3.6 AWH 3.4 AHL 3.0 ENH 1.8 PTP 1.7 MRH 1.6 AGII Notes 1. Excluding non-controlling interest 6 Endurance
Endurance Overview Company Description Endurance Specialty Holdings Ltd., through its subsidiaries, underwrites specialty lines of property and casualty insurance and reinsurance worldwide Endurance writes agriculture, casualty and other specialty, professional and property lines of insurance and catastrophe, property, casualty, professional and other specialty lines of reinsurance Endurance distributes its products directly, as well as through independent agents, and insurance and reinsurance brokers Endurance was founded in 2001 Business Mix (2013 Gross Premiums Written) Reinsurance 45% Casualty & Specialty (1) 20% Property 11% Catastrophe 13% Insurance 55% Agriculture 36% Property 2% Casualty & Other Specialty 12% Professional Lines 6% Notes 1. Includes Professional Lines reinsurance segment 2. Operating income available to common and participating shareholders 3. Annualized Recent Operational Performance $MM, Except %s Income Statement & Balance Sheet Gross Premiums Written % Growth Net Premiums Earned Operating Earnings (2) Operating EPS Shareholders Equity Loss and LAE Reserves Key Metrics Loss Ratio (%) Expense Ratio (%) Combined Ratio (%) Investment Yield (%) Operating ROE (%) 2011 2,467 20.2% 1,931 (152) (3.81) 2,611 3,824 84.6% 28.3% 112.9% 2.4% (6.3%) 2012 2,549 3.3% 2,014 54 1.25 2,711 4,241 75.5% 26.8% 102.3% 2.8% 2.4% 2013 2,665 4.6% 2,016 281 6.41 2,887 4,002 60.5% 29.7% 90.2% 2.6% 11.9% 1Q14 1,158 N/A 396 94 2.12 3,001 3,848 44.6% 36.7% 81.3% 2.6% 15.0%(3) 7 Endurance
Endurance Overview (contd) Endurances strategy has been strongly supported by the investment community Share Price Performance: Endurance vs. Peers (1) 1/1/2013 4/11/2014 % 50 40 30 20 10 0 +36% +29% +23% Jan-13 Apr-13 Jul-13 Oct-13 Jan-14 Apr-14 ENH AHL Peers Average Notes 1. Peers include ACGL, AGII, AWH, AXS, MRH, PRE, PTP, RE, RNR, VR and XL 2. Permission to use quoted material neither sought nor obtained Equity Research #1 (2) The company has laid out a goal to dramatically grow its insurance premiums over the next three years excluding its crop business. The fourth quarter already demonstrated signs of such growth. Excluding crop, the gross insurance premiums grew by 27% in the quarter. As new teams join the company and Endurance expands its presence in London, we would expect this double digit [growth] to continue. - February 6, 2014 Equity Research #2 (2) Earlier this week, we spent a day with recently appointed CEO John Charman visiting with investors. We walked away from the meetings with increased confidence in Endurances long-term prospects, with the company now having the vision and direction it has long lacked and a plan for growth that we see as largely achievable over a three-year period. - December 6, 2013 Equity Research #3 (2) Mr. Charman has an excellent long-term underwriting track record, particularly in specialty insurance Mr. Charman made a name for himself in the London insurance market. The syndicate he ran dramatically outperformed the Lloyds market over a 13 year period before he left. Axis performed well during Mr. Charmans time at the helm with compound annual growth in book value of 14% (including dividends). - May 28, 2013 8 Endurance
Aspen Overview Company Description Aspen Insurance Holdings Limited, through its subsidiaries, operates in insurance and reinsurance businesses worldwide Aspens insurance segment offers property insurance, casualty insurance, marine, energy and construction liability and other specialty insurance products. Its reinsurance segment offers property catastrophe reinsurance, other property reinsurance, casualty reinsurance, and specialty reinsurance Aspen provides its products primarily through brokers and reinsurance intermediaries Aspen was founded in 2002 Business Mix (2013 Gross Premiums Written) Reinsurance 43% Casualty & Specialty 21% Other Property 11% Property Catastrophe 10% Insurance 57% Property 9% Casualty & Other Specialty (1) 16% Financial & Professional Lines 13% Marine, Energy & Transportation 20% Notes 1. Includes Programs insurance segment 2. Calculated as net investment income and realized gain on securities divided by average cash and investments 3. Annualized Recent Operational Performance $MM, Except %s Income Statement & Balance Sheet Gross Premiums Written % Growth Net Premiums Earned Operating Earnings Operating EPS Shareholders Equity Loss and LAE Reserves Key Metrics Loss Ratio (%) Expense Ratio (%) Combined Ratio (%) Investment Yield (%) (2) Operating ROE (%) 2011 2,208 6.3% 1,889 (110) (1.32) 3,156 4,525 82.4% 33.5% 115.9% 3.4% (3.4%) 2012 2,583 17.0% 2,084 280 3.38 3,488 4,780 59.4% 34.9% 94.3% 2.9% 8.5% 2013 2,647 2.5% 2,172 304 3.88 3,350 4,679 56.3% 36.3% 92.6% 2.9% 9.7% 1Q14 856 N/A 567 113 1.55 3,387 4,761 50.9% 36.7% 87.6% 3.0% 14.8%(3) Share Price Performance Initial Proposal (4/11) $45.42 Increased Proposal (6/2) $50 $45 $40 $35 $30 Jun-13 Apr-14 Jun-14 Aug-13 Oct-13 Dec-13 Feb-14 9 Endurance
Aspen Overview (contd) Performance has consistently lagged peers Aspen faces long-term challenges in terms of scale, competition and global breadth Performance has consistently lagged its competitors, including Endurance, across most key metrics On its own, Aspen has no obvious catalyst to meaningfully improve its competitive position and returns Even as Endurance has significantly outperformed Aspen, Endurances board and management have taken meaningful steps to improve positioning and performance of the company Combined Ratio (1) 2009-2013 120% 110% 100% 90% 80% 70% 2009 2010 2011 2012 2013 Aspen Endurance Peers Average BVPS Growth (1) 2009-2013 CAGR 12% 10% 8% 6% 4% 2% 0% Aspen Endurance Peers Average Aspen Endurance Peers Average Last 5 Years Share Price Performance (1) Through 4/11/2014, Rebased to Aspen Share Price $50 $45 $40 $35 $30 $25 $20 Apr-09 Apr-10 Apr-11 Apr-12 Apr-13 Apr-14 +96% +92% +66% Aspen Endurance Peers Average Source Company filings Last 5 Years P/BV (1) Through 4/11/2014 1.20x 1.10x 1.00x 0.90x 0.80x 0.70x 0.60x 0.50x Apr-09 Apr-10 Apr-11 Apr-12 Apr-13 Apr-14 1.03x 0.98x 0.96x Aspen Endurance Peers Average Notes 1. Peers include ACGL, AGII, AWH, AXS, MRH, PRE, PTP, RE, RNR, VR and XL 10 Endurance
Aspen and Endurance: A Unique Opportunity to Create a Global Leader in the Specialty Insurance and Reinsurance Sector Increased Scale and Market Presence Diversified Platform Across Products and Geographies Strong Balance Sheet and Capital Position Enhanced Profitability Combination creates an enterprise with over $5 billion of annual gross premiums written Expanded leadership and underwriting expertise Increased size allows organization to better capitalize on distribution relationships Greater scale better positions combined company to compete with largest players as competition intensifies Endurance and Aspen share certain common businesses; however, the relative weighting of each is quite complementary Aspens strength in the Lloyds market and Endurances market-leading U.S. agriculture business are examples of uncorrelated and diversified businesses The global breadth and diversity of the combined business will be more relevant for brokers and customers Aspens Lloyds platform complements Endurances global insurance and reinsurance footprint and is highly attractive to Endurance With shareholders equity of $5.9 billion and total capital of $7.3 billion (1), the combined company will have scale comparable to many of its key competitors Larger, stronger balance sheet will be better positioned to pursue growth and withstand volatility Additional capital efficiencies due to improved business diversification anticipated Transaction synergies anticipated to be in excess of $100MM through cost savings, underwriting improvements, capital efficiencies and enhanced capital management opportunities Combined company will be well positioned to produce an improved ROE Larger asset base will enable the combined company to capitalize on investment opportunities as they arise Notes 1. Balance sheet figures as of 3/31/2014, market data as of 6/30/2014. Figures shown are pro forma for transaction and reflect the permanent financing plan, assuming no exercise of CVCs option to purchase $250MM of Endurance common shares post-closing; shareholders equity excludes non-controlling interest 11 Endurance
Transaction Terms Endurances proposal provides compelling value for Aspen shareholders while generating significant earnings and ROE accretion for Endurance shareholders Transaction Proposal Value Consideration Financing Endurance CEO Investment Pro Forma Ownership Financial Benefits Endurance to acquire all of the common shares of Aspen Proposal values Aspen at $49.50 (1) per share or $3.2 billion (2) 1.16x Aspens diluted book value per share at 3/31/2014 and 11.8x 2014 consensus Street earnings estimates 25.7% premium to Aspens unaffected closing share price on 4/11/2014 and 19.5% premium to (pre-announcement) all-time high The consideration is based on Endurances unaffected closing share price on 4/11/2014. Based on Endurances closing share price on 6/30/2014, Endurances proposal would value Aspen at $48.27 per share (3) Aggregate consideration mix of 40% cash and 60% stock Aspen shareholders can elect to receive (i) $49.50 in cash for each Aspen share, (ii) 0.9197 Endurance common shares for each Aspen share, or (iii) a combination of 0.5518 Endurance common shares and $19.80 in cash for each Aspen share, subject to a customary proration mechanism Proposal structured to be tax-free to Aspen common shareholders with respect to the Endurance common shares received in the transaction $1.3 billion of cash consideration to be funded through Endurances cash on hand and $1.0Bn committed bridge financing Financing to replace bridge facility currently anticipated to be generated from Aspen cash on hand of $0.2Bn, public investment grade debt financing of ~$0.3Bn and common equity financing of ~$0.5Bn Pro forma debt to total capital of 19% at 3/31/2014, expected to be approximately 15% by end of 2015 (4) John Charman, Endurances Chairman and Chief Executive Officer, has committed to purchase $25 million of Endurance common shares in connection with the transaction, bringing his total purchases of Endurance shares to $55 million 49% by Endurance shareholders (including John Charman) 40% by Aspen shareholders 11% by New Investors (5) Significant EPS and ROE accretion for Endurance shareholders Over $100 million of annual synergies anticipated Notes 1. Based on Endurances unaffected closing share price of $53.82 as of 4/11/2014 2. Based on 67.1MM fully-diluted Aspen shares as of 6/11/2014 and Endurances share price as of 6/30/2014 of $51.59 3. Based on pro rata consideration mix of 40% cash and 60% stock 4. Reflects permanent financing plan and assumes repayment of Endurances $200MM senior debt maturing in October 2015 5. Assumes $0.5Bn of common equity issued to new investors at 3% discount to Endurances closing share price of $51.59 as of 6/30/2014; assumes no exercise of option by CVC to purchase $250MM of Endurance common shares post-closing 12 Endurance
Endurance Offer for Aspen Per Aspen Share (1) Premium to Aspen Share Price % Premium to Unaffected Share Price % Premium to Unaffected All-time High (2) Valuation Multiples P/BV (12/31/13) P/BV (3/31/14) P/E 14E (3) P/E 15E (3) 4/14/2014 Initial Offer 6/2/2014 Increased Offer $47.50 20.7% 14.7% 1.16x 1.11x 13.4x 12.1x $49.50 25.7% 19.5% 1.21x 1.16x 11.8x 12.4x Notes 1. Based on Endurances unaffected closing share price of $53.82 as of 4/11/2014, the last trading day before the announcement of Endurances initial offer 2. All time high share price of $41.43 prior to announcement of Endurances initial offer on 4/11/2014 3. Initial offer based on consensus Street estimates of $3.55 for 2014 and $3.93 for 2015 as of 4/11/2014; increased offer based on consensus Street estimates of $4.20 for 2014 and $4.00 for 2015 as of 6/30/2014 13 Endurance
Clear Contrast in Corporate Governance Aspens Poor Corporate Governance Practices Board is classified, with directors serving three year terms Directors can only be removed for cause Board adopted a poison pill in April 2014 that prevents shareholders from realizing the benefits of transaction proposals such as that brought by Endurance Amazingly, Aspen believes that empowering its shareholders to vote is coercive Aspen insiders own less than 1.2% of the company Special strategy committee created by Aspen board to consider proposed transaction is not comprised solely of independent directors and includes Aspen CEO Chris OKane a clear conflict of interest Substantial withhold votes for Chris OKane (over 20% of shares voted) and other Aspen directors at 2014 annual general meeting, after the rejection by Aspen of Endurances initial acquisition proposal In April 2014, following public announcement of Endurances initial acquisition proposal, Chris OKane received a share grant that was 26% larger than his 2013 share grant At the direction of current management, Aspen has acquired over 200 works of art an unnecessary and wasteful diversion of managements time and corporate assets Endurance Alignment with Shareholders Entire board stands for reelection on an annual basis, with a majority vote standard Directors can be removed by shareholders for any reason No poison pill Endurance encourages and respects the views of shareholders Endurance insiders own 5.2% of the company and Chairman and CEO John Charman continues to invest his own personal capital in the company, including a commitment to invest an additional $25MM as part of the proposed transaction Endurance board created committee to evaluate the proposed transaction comprised solely of independent directors John Charman reelected to Endurances board with over 98% of the vote at 2014 annual general meeting, after the announcement of Endurances initial proposal to acquire Aspen Endurances board and management focus their efforts on increasing shareholder value Aspens board has refused to engage in any discussions with Endurance regarding the proposal From Endurances numerous discussions with shareholders, we believe Aspen shareholders are supportive of engagement Top 25 Aspen shareholders own 60% of Aspens outstanding common shares and 40% of Endurances common shares 14 Endurance
Transaction Timeline Endurances Commitment and Aspens Entrenchment January 30, 2014: John Charman approaches Aspen CEO to discuss a strategic transaction between Endurance and Aspen February 13, 2014: Aspen CEO advises that Aspen declines to meet with Endurance February 18, 2014: Endurance delivers initial confidential proposal to Aspens board for Endurances acquisition of Aspen for $47.50 per share (a 14.7% premium to Aspens unaffected all-time high trading price) March 18, 2014: Endurance receives letter from Aspen stating its board did not wish to pursue a transaction with Endurance April 3, 2014: Endurance delivers to Aspens board a letter stating Endurance remained fully committed to pursuing a transaction April 8, 2014: Endurance receives letter from Aspen again declining to meet with Endurance or its advisers April 14, 2014: Endurance delivers letter to Aspens board and issues press release announcing the initial Endurance proposal Aspen issues press release rejecting the initial proposal April 17, 2014: Aspen announces adoption of poison pill May 7, 2014: Endurance communicates an increased proposal to acquire Aspen at $49.50 per share (a 19.5% premium to Aspens unaffected all-time high trading price) through confidential conversations between financial advisers May 12, 2014: Aspen rejects Endurances increased proposal and again refuses to enter into discussions with Endurance June 2, 2014: Endurance delivers letter to Aspens board and issues press release publicly announcing (i) the increase in consideration, (ii) filing of a solicitation statement, (iii) its intention to commence an exchange offer, and (iv) the bridge loan facility commitment from Morgan Stanley Aspen again rejects Endurances increased proposal June 9, 2014: Endurance commences exchange offer for all Aspen common shares June 17, 2014: Aspen issues press release and presentation, and files preliminary revocation solicitation statement and Schedule 14D-9 June 18, 2014: Endurance commences solicitation of Aspen shareholders for two proposed authorizations by mailing definitive solicitation statement and letter to shareholders June 27, 2014: Aspen mails revocation solicitation statement and letter to shareholders Endurance issues second letter to Aspen shareholders with respect to Endurances two proposed shareholder authorizations July 25, 2014: Target date for Aspen shareholders to vote on Endurances two proposals Public Action Private Action 15 Endurance
Aspens Continued Entrenchment has Required Endurance to Provide a Path Forward to Aspen Shareholders Actions to expedite transaction further demonstrate Endurances commitment to pursuing this transaction while providing Aspen shareholders multiple means to voice support and complete transaction in spite of Aspens refusal to engage Seeking a special general meeting to approve increase in the size of Aspens board Supporting proposal of a Scheme of Arrangement by Endurance Commenced exchange offer for all Aspen common shares Proposal to increase size of Aspen board from 12 to 19 directors Provides Aspens shareholders the ability to replace the majority of Aspens board at the 2015 annual general meeting Scheme of Arrangement would entail the holding of a court ordered meeting for Aspen shareholders to approve Endurances increased proposal Scheme of Arrangement would allow completion of the transaction without the approval of Aspens board Exchange offer directly to Aspens shareholders for all Aspen common shares reflecting the same economic terms as Endurances increased proposal 16 Endurance
Endurance Strategic Rationale and Compelling Value of Endurances Proposal
Key Benefits of Endurances Proposal 1 Value 2 Scale 3 Diversification 4 Financial Strength 5 Outlook Aspen Standalone Valuation has trailed that of peers over the past 5 years: up only 66% vs. 96% for peers (1) Historically traded below book value Disadvantaged relative to peers due to lack of scale Underutilized infrastructure Concentration in marine, energy and transportation insurance Shareholders equity of $3.4Bn and single-digit ROE No obvious catalyst to meaningfully improve its competitive position and returns Analysts remain unconvinced about Aspens ability to deliver on its ROE targets Endurance / Aspen Pro Forma 25.7% premium to Aspens unaffected share price, 19.5% premium to Aspens all-time high (pre-announcement) Implied multiple of 1.16x 3/31/2014 diluted BVPS represents higher premium than comparable transactions (2) $5Bn pro forma gross premiums written enable combined company to be a market leader with increased importance to brokers Balanced, global presence in core markets Optimize line of business and geographic exposure (e.g., U.S. agriculture, Lloyds, marine & energy) Pro forma shareholders equity of $5.9Bn and anticipated ROE of 12% 14% Potential for ratings upgrade over time Combination and pro forma profile creates basis for valuation in-line with best-in-class peers Endurances proposal provides value to Aspen shareholders in excess of what they could achieve on a standalone basis in two years based on consensus Street estimates for Aspens ROE Notes 1. Through 4/11/2014; peers include ACGL, AGII, AWH, AXS, MRH, PRE, PTP, RE, RNR, VR and XL 2. Includes Alterra / Markel, Paris Re / Partner Re, Transatlantic / Alleghany, IPC / Validus, HarborPoint / Max Capital, Flagstone / Validus 18 Endurance
Proposed Valuation Well Above Aspens Historical Trading Prices Aspen Share Price Last 5 Years 4/11/2009 4/11/2014 $50 $49.50 $40 $39.37 $30 $20 Apr-09 Apr-10 Apr-11 Apr-12 Apr-13 Historical Share Price Endurance Purchase Price Aspen P/BV Last 5 Years 4/11/2009 4/11/2014 1.25x 1.16x 1.00x 0.96x 0.75x 5-Yr Average: 0.79x 0.50x Apr-09 Apr-10 Apr-11 Apr-12 Apr-13 Historical P/BV Endurance Purchase Price Performance illustrated through April 11, 2014 the trading day prior to initial proposal announcement 19 Endurance
Proposal Provides Compelling Value for Aspen Shareholders Substantial Premium to Trading Prices Proposal Price Per Share $49.50 vs. Price as of 4/11/2014 $39.37 +25.7% vs. 1-month VWAP (1) $39.27 +26.1% vs. All Time High (2) $41.43 +19.5% Attractive Valuation Multiples Proposal Price Per Share $49.50 vs. Diluted BVPS at 12/31/13 $40.90 1.21x vs. Diluted BVPS at 3/31/14 $42.72 1.16x vs. 5-year Average P/BV (2) 0.79x +46.7% vs. 2014E Earnings (3) $4.20 11.8x vs. 2015E Earnings (3) $4.00 12.4x Notes 1. For the 30 calendar days ending 4/11/2014 2. All time high and 5-year average P/BV prior to announcement of Endurances initial proposal on 4/11/2014 3. Based on consensus Street estimates for 2014 and 2015 EPS as of 6/30/2014 20 Endurance
Comparable Transaction Analysis Comparison of P/BV multiples for selected Bermuda / Reinsurance transactions Aspen / Endurance 1.16x Alterra / Markel 1.07x Paris Re / Partner Re 0.98x Transatlantic / Alleghany 0.85x IPC / Validus 0.84x HarborPoint / Max Capital 0.80x Flagstone / Validus 0.73x 0.00x 0.20x 0.40x 0.60x 0.80x 1.00x 1.20x 1.40x Endurances proposal is at a significant premium to the unaffected market valuation of Aspen and at a higher price / book multiple than comparable transactions 21 Endurance
Combined Company Will Have Scale to Compete With Market Leaders Gross Written Premiums of Peer Companies $Bn, for the year ended 12/31/2013 10.0 7.7 8.0 6.0 5.6 5.3 5.2 4.7 4.2 4.0 2.7 2.7 2.6 2.4 1.9 1.6 2.0 0.7 0.6 0.0 XL PRE ENH+AHL RE AXS ACGL AWH ENH AHL VR AGII RNR MRH PTP Shareholders Equity of Peer Companies (1) $Bn, as of 3/31/2014 12.0 10.2 10.0 8.0 7.0 6.8 5.9 5.9 5.8 6.0 3.8 3.6 3.6 3.4 4.0 3.0 2.0 1.8 1.7 1.6 0.0 XL RE PRE ACGL ENH+AHL(2) AXS RNR VR AWH AHL ENH PTP MRH AGII Notes 1. Excluding non-controlling interest 2. As of 3/31/2014, pro forma for transaction and reflects permanent financing plan, assuming no exercise of CVCs option to purchase $250MM of Endurance common shares post-closing 22 Endurance
Scale Advantages for a Combined Endurance / Aspen Strategic Advantages of a Larger Capital Base Lower cost of capital afforded by scale provides competitive advantage in the face of increasing capital market capacity Mitigates continued pricing pressures, especially in reinsurance Greater influence / control over terms and conditions when negotiating with intermediaries Demand for larger and more diversified reinsurance partners is increasing as primary insurers expand globally Reinsurance brokers favor reinsurers with larger balance sheets and more product offerings Market Opportunities Opportunity to grow operations to scale and optimize geographic exposure as market conditions warrant Build around existing competencies such as Lloyds and agriculture Stronger relationships with major insurance and reinsurance intermediaries Increased opportunities for role as market leader Opportunities for differentiated pricing in certain lines Enhanced profitability through cost efficiencies across a larger platform 23 Endurance
Combined Business Well Diversified Across Business Lines and Sectors Geographic and distribution diversification benefits are also achieved Full Year 2013 Gross Written Premiums Endurance Reinsurance 45% Insurance 55% Casualty & Specialty (1) Agriculture 36% 20% Property 11% Catastrophe Property 2% 13% Casualty & Other Specialty 12% Professional Lines 6% GPW: $2.7Bn Aspen Reinsurance 43% Insurance 57% Property 9% Casualty & Specialty Casualty & Other Specialty (2) 16% 21% Other Property 11% Financial & Professional Lines 13% Property Catastrophe 10% Marine, Energy & Transportation 20% GPW: $2.6Bn Combined Reinsurance 44% Insurance 56% Casualty & Specialty (1) 21% Agriculture 18% Property 5% Property 11% Casualty & Other Specialty (2) 14% Catastrophe 12% Professional Lines 9% Marine, Energy & Transportation 10% GPW: $5.3Bn Notes 1. Includes Professional Lines reinsurance segment for Endurance 2. Includes Programs insurance segment for Aspen Endurance 24
Transaction Generates Meaningful Synergies and Financial Strength Key Financial Drivers Over $100 million of annual synergies anticipated, including: Cost savings Underwriting improvements Capital efficiencies Enhanced capital management opportunities Combined Balance Sheet Strength (1) Endurance Pro Forma at 3/31/2014 Shareholders Equity (2) $ 3.0Bn $5.9Bn Cash and Invested Assets $ 6.7Bn $14.4Bn Total Capital $ 3.5Bn $7.3Bn Summary of Financial Impact to Endurance EPS (3) >15% accretion anticipated in 2015 ROE (3) 12 14% pro forma ROE anticipated in 2015; >200bps increase vs. standalone Endurance ROE Modest initial dilution to book value per share anticipated, offset by the significant accretion to Book Value Per Share both ROE and EPS in 2015 Notes 1. Balance sheet figures as of 3/31/2014, market data as of 6/30/2014. Figures shown are pro forma for transaction and reflects entering into bridge loan facility commitment and takeout through permanent financing plan, assuming no exercise of CVCs option to purchase $250MM of Endurance common shares post-closing 2. Excluding non-controlling interests 3. Excluding integration charges Endurance 25
Superior Pro Forma Financial Profile Aspen Standalone Endurance / Aspen Pro Forma (1) Shareholders Equity $3.4Bn (3/31/14) $5.9Bn (3/31/14) Total Debt / Capital 15% (3/31/14) 19% (3/31/14) 15% (12/31/15) Total Debt + Preferred / Capital 29% (3/31/14) 33% (3/31/14) 28% (12/31/15) Net Income 2015E $258MM $625MM - $725MM 9.1% Street 12%-14% ROE 2015E 11.0% Management Endurances proposal provides Aspen shareholders with superior financial strength Notes 1. Reflects permanent financing plan, assumes repayment of Endurances $200MM senior debt maturing in October 2015 and no exercise of CVCs option to purchase $250MM of Endurance common shares post-closing Endurance 26
Aspen Underperformance Under Current Management 5 Year Performance(1) Aspen Endurance Total Return to Shareholders 83% 124% Diluted Book Value Per Share 9.4% CAGR 13.0% CAGR Growth Underwriting Profitability (Combined 96.7% 95.6% Ratio) Efficiency (Expense Ratio) 33.5% 29.0% Endurance has performed better than Aspen on all four key performance measures over the past five years Notes 1. Financial metrics shown (excluding total shareholder return) are for the five years ended 12/31/2013. Total shareholder return for the 5 years preceding the announcement of Endurances initial proposal on 4/11/2014 Endurance 27
Analysts Forecast Limited Improvement for Aspens Standalone ROE Equity Research #1 Thoughts on ROE Outlook: AHLs ROE in this quarter was 14.9%, however if we normalize for cat losses and reserve releases in excess of our forecast we get ROE closer to 9%. We continue to have difficulty finding the levers in our model to get to an ROE close to managements targets for 2014. - April 24, 2014 Equity Research #2 It might be argued that our assumptions for 2014 are too generous. We believe there might be some risk to our numbers. However, managements confidence in achieving its 10% ROE leaves us looking for ways to get there. Ironically, we cannot find any path to a 10% ROE defined as operating income divided by total common equity, the way management calculates ROE. We believe, on this basis, there is a high probability of a guidance miss. - February 24, 2014 2014 ROE 2015 ROE Equity Research 8.9% 8.8% Analyst A Equity Research 9.4% 8.2% Analyst B Equity Research 9.7% 8.1% Analyst C Equity Research 9.8% 9.3% Analyst D Equity Research 9.8% 10.0% Analyst E Equity Research 10.4% 10.3% Analyst F Mean 9.7% 9.1% Median 9.8% 9.1% Note: Permission to use quoted material neither sought nor obtained Endurance 28
Transaction Provides Substantial Premium vs. Standalone Plan and Significant Upside Potential to Aspen Shareholders The transaction provides Aspen shareholders the ability to achieve values meaningfully higher than Aspens future value implied by consensus Street estimates for Aspens ROE and recent Aspen management ROE guidance It will take Aspen over 2 years to surpass the $49.50 proposed acquisition price based on consensus Street estimates for Aspens ROE Historical Aspen Illustrative Future Value of Aspen Shares (1)(2) Share Price $90 $81 $80 Pro forma at 12-14% ROE (3) $70 $65 $60 Aspen standalone at $55 management guidance (4) $49.50 $51 Aspen standalone at $50 $53 consensus Street $46 estimates (5) $49 $39.37 $46 $40 $30 -1 Year Pre-Announcement +1 Year +2 Years +3 Years Notes 1. Assumes Aspen shareholders receive 0.9197 shares of Endurance for each share of Aspen 2. Assumes Aspen and pro forma dividend yield maintained at current level as of 4/11/2014 in all scenarios; dividend yield based on trailing 12-months dividends per share divided by current share price 3. Assumes P/BV of 1.0x-1.2x for 12-14% ROE 4. Assumes P/BV of 1.0x; Aspens management guidance of 10% ROE in 2014 and 11% ROE for 2015 and 2016 per first quarter 2014 investor presentation dated 5/20/2014 5. Assumes P/BV of 1.0x; consensus Street estimates for Aspens ROE based on median 2014 ROE estimate of 9.8% for +1 year and median 2015 ROE estimate of 9.1% for +2 years and +3 years; estimates as of 6/30/2014 Endurance 29
Analysts Recognize Strategic and Financial Benefits of Combination and Support Engagement Equity Research #1 We suspect that current AHL shareholders will ask the AHL board to reconsider this transaction and/or look for competitive offers. Looking over the landscape we do not see too many competitors that would be willing to pay a similar premium to book value for AHL. - April 15, 2014 Equity Research #2 Given softening market conditions (especially in reinsurance), the entry of 3rd party capital (pension/hedge fund), excess capital (everywhere), shrinking loss reserve redundancies, low interest rates, the competitive advantages of size, weve discussed the increasing attractiveness of combinations in Bermuda From Endurances perspective the move in line with managements stated strategy of developing market relevance (with both clients and brokers) through increased sophistication, diversification and scale. - April 17, 2014 Equity Research #3 [W]ith P&C pricing decelerating, and an outright soft market in reinsurance, we see cost-driven consolidation among the Bermuda group as strategically logical and shareholder friendly [A] combined entity would be a solid mid-cap name with a capital base towards the larger end of its peer group The companies also have complementary strengths, as Endurance is underweight in London and does not have a Lloyds syndicate one of the strongest aspects of Aspens business. Further, ENHs crop insurance business, while currently over-weight relative to its size, would provide a more balanced contribution to the combined underwriting portfolio, and deliver a revenue stream that is not correlated to the P&C pricing cycle. - April 30, 2014 Equity Research #4 A combined company would have notably increased scale, the benefit of enhanced market presence and increased diversification (products and geographies). There are several aspects of each companys specialty business that are complementary such as ENHs crop and Aspens Lloyds operation and marine/energy lines. ENH has limited market presence in London. With pressure building in reinsurance, size and scale will be increasingly important and we would expect to see consolidation activity pick up. - June 2, 2014 Note: Permission to use quoted material neither sought nor obtained Endurance 30
Endurance Endurances Actions to Expedite the Transaction
Endurances Actions to Expedite the Transaction Path for Aspens Shareholders to Realize the Benefits of Endurances Proposal Action 1: Special General Meeting of Aspen Shareholders Solicitation statement mailed to Aspen shareholders on June 18, 2014 seeking the support of Aspens common shareholders to convene a special general meeting of Aspen shareholders at which they would consider a proposal to increase the size of Aspens board from 12 to 19 directors Calling special general meeting requires support of at least 10% of Aspens outstanding common shares Endurance has set a target date of July 25, 2014 for Aspen shareholders to vote on this action If the special general meeting is held, and the proposal is approved, a majority of Aspens directors would stand for election at Aspens 2015 annual general meeting Action 2: Supporting Proposal of Scheme of Arrangement by Endurance Solicitation statement also seeks the support of Aspens shareholders for the proposal of a Scheme of Arrangement by Endurance, which will entail the holding of a court-ordered meeting at which Aspens shareholders would vote on a Scheme of Arrangement on financial terms no less favorable than those contained in Endurances increased proposal If Endurance receives the support of holders of at least 15% of Aspens outstanding common shares for this action, Endurance intends to apply to the Supreme Court of Bermuda to order such court-ordered meeting(1) Endurance has set a target date of July 25, 2014 for Aspen shareholders to vote on this action Aspens poison pill is not anticipated to be an impediment to completing a Scheme of Arrangement The Scheme of Arrangement can be accomplished without the approval of the Aspen board if approved by Aspen shareholders at two shareholder meetings and sanctioned by the Supreme Court of Bermuda Action 3: Exchange Offer On June 9, 2014, Endurance commenced an exchange offer directly to Aspens shareholders for all Aspen common shares Exchange offer expires 5:00 p.m., Eastern time, on Friday, August 29, 2014, unless extended Notes 1. In determining to set the threshold at 15%, Endurance considered that under Bermuda law, the holders of at least 10% of the voting share capital of Aspen have the statutory right to requisition a special general meeting of shareholders, and that the 15% threshold to evidence support for a court-ordered meeting of shareholders is a 1.5x multiple of such 10% amount Endurance 32
Endurances Actions to Expedite the Transaction Scheme of Arrangement A Scheme of Arrangement is a court approved arrangement between a company and its shareholders that would allow Endurance to simultaneously acquire all of the outstanding Aspen common shares Solicitation seeking support of Aspens shareholders for a proposal for a Scheme of Arrangement Support from at least 15% of Aspens outstanding common shares Application to the Supreme Court of Bermuda for court-ordered meeting If granted, hold court-ordered meeting to consider Scheme of Arrangement Hold Aspen special general meeting to allow Aspen shareholders to approve Scheme of Arrangement on behalf of Aspen Requisition Aspen special general meeting to approve Scheme of Arrangement No Aspens board approves Scheme of Arrangement? Support from majority of Aspens holders present at the meeting representing at least 75% in value of votes cast Yes Apply to Supreme Court of Bermuda to sanction the Scheme of Arrangement Support from majority of votes cast at Aspen special general meeting Deliver a copy of the order of the Supreme Court of Bermuda sanctioning the Scheme of Arrangement to the Bermuda Registrar of Companies Endurance 33
Committed Financing Plan Delivering Substantial Cash Consideration to Aspen Shareholders $1.0Bn committed bridge loan facility from a syndicate led by Morgan Stanley to fund, together with cash on hand at Endurance, the cash portion of the consideration payable to Aspens shareholders Endurances proposal is not subject to a financing condition Permanent financing expected to include common equity and investment grade debt on customary terms Pro forma leverage of 19% at 3/31/2014, expected to be approximately 15% by end of 2015 (1) Endurance believes that, pro forma for the transaction, its financial position will be well within the ratings criteria to maintain its current ratings Total Consideration ($Bn) Stock $1.9 Cash $1.3 Total consideration $3.2 (2) Initial Committed / Available Cash Bridge $1.0 Cash on Hand $0.4 Total Sources of Cash $1.4 Permanent Financing Plan ($Bn) (3) Common Equity ~$0.5 Debt ~$0.3 Aspen available cash (est.) $0.2 Total $1.0 Notes 1. Reflects permanent financing plan and assumes repayment of Endurances $200MM senior debt maturing in October 2015 2. Based on 67.1 MM fully-diluted Aspen shares as of 6/11/2014 and an exchange ratio of 0.9197 based on Endurances unaffected closing share price of $53.82 as of 4/11/2014 3. For illustrative purposes only; assumes no exercise of CVCs option to purchase $250MM of Endurance shares post-closing Endurance 34
Endurance Appendix
Insurance Industry Overview Insurance Overview Reinsurance Overview Premiums Commissions & Fees Insurance Purchaser P&C Broker Claims Primary Insurer Ceded Premiums Commissions & Fees P&C Broker Reinsurer Claims Two main types of reinsurance Pro Rata Losses Insurer Reinsurer % of Losses Excess of Loss Losses Reinsurer Insurer Limit Attachment P&C primary insurers provide insurance coverage (a promise to pay) in return for premiums. If covered losses emerge then the carrier pays claims from its loss reserves Investment income is money earned on the investment portfolio. This portfolio or float is largely premiums which are invested before claims are paid out Underwriting profitability is measured by the Combined Ratio which is the sum of (Losses + Expenses)/Net Premiums Earned. The Loss Ratio captures total estimated losses while the Expense Ratio covers the cost of policy acquisition and overhead A combined ratio < 100% = profitable underwriting P&C brokers assist in the placement of risk in return for payment (commissions or fees) but assume no underwriting risk Reinsurers provide insurance for insurance companies looking to lay-off (cede) a portion of their assumed risk Reinsurers absorb volatility (at times catastrophe) risk from insurers Reinsurers are among the largest players in the industry; balance sheet strength is critical Two main types of reinsurance: Pro rata reinsurer shares losses in the same proportion as it shares premiums and policy amounts Excess of Loss coverage for losses above an agreed amount Bermuda Bermuda is a leading global insurance and reinsurance market, particularly for specialty risks Bermudas role as a leading global reinsurance center is driven by: Well-established regulatory framework Large talent pool Convenient access from both U.S. and European markets Low tax rate Endurance 36
Endurance Has Strong Foundation to Build on Strong balance sheet, diversified portfolio and robust infrastructure Strong Balance Sheet and Capital A ratings from AM Best and S&P $3.5 billion of total capital (as of 3/31/2014) Conservative, short-duration, AA rated investment portfolio Prudent reserves Diversified and efficient capital structure Since inception, returned $2.0 billion to investors through dividends and share repurchases Diversified Portfolio of Businesses Portfolio of approximately $2.7 billion in annual gross premiums written Book of business diversified between insurance and reinsurance as well as short tail and long tail lines of business Proven leader in U.S. agriculture insurance business Focus on specialty lines of business, with industry-leading talent Strategic Initiatives Substantially expanded global underwriting and leadership talent Optimized balance of insurance and reinsurance portfolios to lower volatility and improve profitability Streamlined support operations to generate significant savings to fund underwriting additions Improved financial results reflect recent actions Strong and seasoned franchise Inception to date operating ROE of 11.0% 10 year diluted book value per share plus dividends CAGR of 10.6% Continuous improvement in performance and market positioning Endurance 37
Endurance Has an Attractive and Growing Specialty Insurance Franchise Two pillars of a unique insurance platform with demonstrated improvement across specialty lines to complement market-leading agriculture franchise Enhanced Specialty Insurance Franchise Significant and tangible improvements in 2013 to increase market presence and diversity Attracted and retained teams of high quality underwriters Expanded underwriting and product capabilities Withdrew from unprofitable lines Insurance GPW (ex. Agriculture) $MM 200 +41% 150 124 100 88 50 1Q13 1Q14 Established Market Leader in Agriculture ARMtech is a top 5 player in the attractive multi peril crop insurance (MPCI) market Favorable market dynamics with only 17 licensed companies in 2013 Federal government sponsored reinsurance and loss sharing mitigates downside risk 2014 passage of U.S. Farm Bill provides stability going forward Not correlated with broader P&C market Attractive market characteristics Historic average combined ratio less than 90% (1) High risk adjusted returns Insurance Business Has Generated Approximately $200 Million of Underwriting Profits Since Inception With a Combined Ratio of 97% Notes 1. Historic average loss ratio post U.S. Federal cessions has been 82.9% (adjusted for the 2011 Federal reinsurance terms); current expense run rate after A&O subsidy is approximately 6% - 8% Endurance 38
Demonstrated Track Record of Reinsurance Profitability Enhancing profitability by recruiting top flight underwriting talent, developing strategic partnerships with key clients and brokers, and improving underwriting and risk selection Reinsurance business has a demonstrated track record of profitability Over $1 billion of premiums and combined ratio of 77% in 2013 Generated almost $1 billion of underwriting profits with a combined ratio of 92% since inception Strategic Priorities for Global Reinsurance Improve profitability and consistency of results through enhanced market presence, improved underwriting and risk selection Hired Jerome Faure in March 2013 as CEO of Global Reinsurance Completed the consolidation of European reinsurance underwriting in Zurich Focus on profitable growth and diversification through existing and new specialty reinsurance units Manage volatility through improved portfolio management and opportunistic retro purchases Eliminate substandard businesses with insufficient margins Recent Key Hires August 2013 Hired Peter Mills, Head of Global Specialty & Europe P&C Reinsurance October 2013 Hired Chris Donelan, Head of U.S. Reinsurance and team of underwriters January 2014 Hired Marine Reinsurance Team based in Zurich (starting in August 2014) May 2014 Hired Agriculture Reinsurance Team based in Bermuda (starting in July 2014) Growing Profitable Specialty Lines of Reinsurance Business With Less Volatile Exposures Endurance 39
Book Value Per Common Share Growth Comparison Endurance Growth in Diluted Book Value Per Common Share ($) From December 31, 2003 December 31, 2013 10 Year CAGR: 10.6%, 5 Year CAGR: 13.0% $80 $60 10.85 7.13 8.33 9.57 6.13 $40 4.13 1.13 5.13 3.13 0.32 2.13 52.74 50.56 52.88 55.18 $20 44.61 27.91 28.87 35.05 33.06 24.03 23.17 $0 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Book Value Per Share Cumulative Dividends Aspen Growth in Diluted Book Value Per Common Share ($) From December 31, 2003 December 31, 2013 10 Year CAGR: 9.9%, 5 Year CAGR: 9.4% $60 $40 3.72 4.32 4.98 5.69 3.12 1.92 2.52 0.12 $20 0.00 0.72 1.32 38.90 38.21 40.65 40.90 34.14 27.08 28.19 18.17 20.69 18.73 21.83 $0 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Book Value Per Share Cumulative Dividends Endurance 40
Top 25 Shareholders of Aspen (1) Substantial overlap between shareholder bases Firm Aspen Votable Shares (1) % of O/S (2) Endurance Votable Shares (1) % of O/S (2) BlackRock Institutional Trust Co. NA 4,645,566 7.1% 1,441,700 3.3% Fidelity Investments 4,511,868 6.9% 3,952,400 9.1% Vanguard Group 3,833,348 5.9% 2,409,893 5.5% Dimensional Fund Advisors 3,659,417 5.6% 3,273,539 7.5% AllianceBernstein L.P. 1,987,789 3.0% 31,400 0.1% State Street Global Advisors 1,948,572 3.0% 787,820 1.8% Sterling Capital Management Company 1,519,658 2.3% 1,295,838 3.0% Mawer Investment Management 1,439,135 2.2% 0 0.0% Hotchkis & Wiley Capital Management, LLC 1,421,258 2.2% 162,900 0.4% Franklin Resources, Inc. 1,413,780 2.2% 0 0.0% Royce & Associates, Inc. 1,273,987 1.9% 0 0.0% Vaughan Nelson Investment Management 1,144,293 1.7% 0 0.0% American Century Investment Mgmt., Inc. 1,143,122 1.7% 215,495 0.5% Bank of New York Mellon Corp. 1,045,806 1.6% 227,140 0.5% Citadel Investment Group, LLC 896,932 1.4% 20,437 0.0% Pzena Investment Management, L.L.C. 829,137 1.3% 47,200 0.1% Champlain Investment Partners, LLC 804,810 1.2% 1,451,470 3.3% Northern Trust Corp. 800,651 1.2% 619,641 1.4% Schroder Investment Management (NY) 771,210 1.2% 226,374 0.5% Private Management Group, Inc. 739,242 1.1% 0 0.0% Two Sigma Investments LLC 727,918 1.1% 22,380 0.1% J.P. Morgan Asset Management (NY) 709,704 1.1% 6,057 0.0% Prospector Partners 706,503 1.1% 193,300 0.4% Norges Bank Investment Management 680,912 1.0% 398,801 0.9% Columbia Management Invest. Advisors, LLC 642,527 1.0% 746,030 1.7% Top 25 Shareholders Total 39,297,145 60.0% 17,529,815 40.3% Source Georgeson Common Shareholders of Aspen and Endurance Notes 1. As of 5/15/2014 2. Calculated based on 65,458,110 Aspen common shares outstanding as of 6/11/2014 and 43,455,995 Endurance common shares outstanding as of 6/17/2014 Endurance 41
Aspen Management Team and Board Are Not Closely Aligned With Shareholders Endurance Director / Named Executive Officer Ownership Summary Number of Mkt. Value Name Role Common Shares (1) % Ownership (2) ($MM) (3) John Charman Chairman and CEO 1,674,315 3.85 90.1 Robert Spass Director 144,708 0.33 7.8 Michael McGuire Chief Financial Officer 132,474 0.30 7.1 John Kuhn CEO, Global Insurance 51,833 0.12 2.8 Steven Carlsen Director 50,133 0.12 2.7 Joan deLemps Chief Risk Officer 39,655 0.09 2.1 William Bolinder Director 32,612 0.08 1.8 John Baily Director 31,633 0.07 1.7 Norman Barham Director 25,683 0.06 1.4 EVP, Head of Graham Evans 22,004 0.05 1.2 International Insurance Top 10 Directors / Named Executive Officers 2,205,050 5.07 118.7 Total Directors / Named Executive Officers 2,268,278 5.22 122.1 Aspen Director / Named Executive Officer Ownership Summary Number of Mkt. Value Name Role Common Shares (1) % Ownership (2) ($MM) (3) Chris OKane Group CEO 189,311 0.29 7.5 Chairman of Aspen Glyn Jones 91,999 0.14 3.6 and Aspen UK Heidi Hutter Director 57,163 0.09 2.3 Brian Boornazian Chairman, Aspen Re 57,010 0.09 2.2 James Few CEO, Aspen Re 48,057 0.07 1.9 CEO of Aspen Mario Vitale 27,344 0.04 1.1 Insurance Richard Bucknall Director 25,380 0.04 1.0 Liaquat Ahamed Director 19,227 0.03 0.8 Peter OFlinn Director 16,467 0.03 0.6 John Cavoores Director 15,887 0.02 0.6 Top 10 Directors / Named Executive Officers 547,845 0.84 21.6 Total Directors / Named Executive Officers 762,593 1.17 30.0 Notes 1. Includes common shares that may be acquired within 60 days of 6/17/2014 for Endurance directors and executive officers and 6/11/2014 for Aspen directors and executive officers upon (i) the exercise of vested options and (ii) awards issuable for common shares 2. Calculated based on 65,458,110 Aspen common shares outstanding as of 6/11/2014 and 43,455,995 Endurance common shares outstanding as of 6/17/2014 3. Market values based on basic shares and share prices as of 4/11/2014 (ENH - $53.82, AHL - $39.37) Endurance 42
Summary of Bridge Term Loan Facility Material Terms Facility Lenders Commitment Termination Date Maturity Pricing Prepayments Financial Covenants Conditions $1.0Bn 364-Day Senior Unsecured Bridge Term Loan Facility Syndicate led by Morgan Stanley December 31, 2014, or if an acquisition agreement is entered into on or prior to December 31, 2014, the earliest to occur of (i) the termination date specified in the acquisition agreement, (ii) 6 months from the execution of the acquisition agreement plus up to an additional 3 months to obtain regulatory approvals to the extent deemed advisable by Endurance to effect the acquisition (and to the extent the termination date under the acquisition agreement is similarly extended) and (iii) 15 months from the date of the commitment letter for the Bridge Term Loan Facility 364 days following any funding of the Bridge Term Loan Facility Customary structuring, upfront and funding fees Draws on the facility will be priced on a ratings based grid. At Endurances current ratings: Days 1-89: L+ 150 bps Days 90-179: L + 175 bps Days 180-269: L + 200 bps Days 270-364: L + 250 bps Ticking / commitment fees: After 60 days, 20.0 bps per annum, increasing to 30.0 bps per annum on December 31, 2014 and ending on the closing date on the undrawn commitments outstanding under the Bridge Term Loan Facility Duration fees (on bridge loans outstanding): 50 bps payable 90 days after funding 75 bps payable 180 days after funding 100 bps payable 270 days after funding Prepayable at any time at par Mandatory prepayments/commitment reductions: net cash proceeds from debt, equity and convertible issuances and non-ordinary course asset sales (subject to certain exceptions) Minimum Consolidated Tangible Net Worth of $1.8Bn Maximum Debt / Capitalization of 40% until the last day of the third fiscal quarter following the acquisition of Aspen, after which it is 35% Customary, including (i) minimum credit ratings of Baa3 (with stable outlook) from Moodys and BBB- (with stable outlook) from S&P, (ii) minimum financial strength ratings of A- (with stable outlook) from S&P and A- (with stable outlook) from A.M. Best, and (iii) except in the case of a negotiated transaction, consolidated tangible net worth, pro forma for the acquisition, of not less than $3.9 billion Endurance 43
Continued Support from Equity Investor Endurance and CVC have terminated the previously announced equity commitment letter, which had been developed under the context of a friendly, negotiated transaction Since Aspens board and management have refused to engage with Endurance, Endurance was compelled to take additional actions Given CVCs continued support for the merits of a combination of Endurance and Aspen, Endurance has granted CVC: Option to invest $250 million (1) in the combined company, exercisable for 60 days following the closing of Endurances acquisition of Aspen Right of first refusal to provide any privately raised equity capital in connection with Endurances permanent financing plan for the transaction subject to certain exceptions Endurance does not intend to privately raise equity capital in connection with such permanent financing, but reserves the right to do so Notes 1. CVC may invest $250MM at a price of $50.03 per Endurance common share (6.5% discount to the 20 trading day volume-weighted average NYSE stock price of Endurance on 4/11/2014 of $53.51). If the option is exercised, CVC will receive warrants to purchase Endurance common shares equal to 38.5% of the number of Endurance common shares purchased at an exercise price of $58.86 Endurance 44
Endurance and Aspen: Creating a Global Leader in Specialty Insurance and Reinsurance Endurance 45